{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:42:05Z","timestamp":1792730525679,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.diabres.2026.113345","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T06:54:06Z","timestamp":1779864846000},"page":"113345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Repurposing GLP-1 receptor agonists and SGLT-2 inhibitors in neurodegeneration and metabolically at-risk populations: Myth or reality? An overview of randomized clinical trials"],"prefix":"10.1016","volume":"237","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9147-8218","authenticated-orcid":false,"given":"Michail-Angelos","family":"Mourtzos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6899-684X","authenticated-orcid":false,"given":"Dimitrios","family":"Patoulias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7483-7165","authenticated-orcid":false,"given":"Natalia-Maria","family":"Keklikoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3561-5713","authenticated-orcid":false,"given":"Paschalis","family":"Karakasis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3893-8878","authenticated-orcid":false,"given":"Valeria Gutierrez","family":"de Pi\u00f1eres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5512-2388","authenticated-orcid":false,"given":"Konstantinos","family":"Stefanakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9549-8504","authenticated-orcid":false,"given":"Manfredi","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3755-8158","authenticated-orcid":false,"given":"Christos S.","family":"Mantzoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2026.113345_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102357","article-title":"Neurodegenerative disorders: Mechanisms of degeneration and therapeutic approaches with their clinical relevance","author":"Gadhave","year":"2024","journal-title":"Ageing Res Rev Elsevier Ireland Ltd"},{"key":"10.1016\/j.diabres.2026.113345_b0010","series-title":"Cureus","article-title":"Glucagon-Like Peptide-1 Receptor Agonists in Neurodegenerative Diseases: A Comprehensive Review","author":"Ibrahim","year":"2025"},{"key":"10.1016\/j.diabres.2026.113345_b0015","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-022-00524-0","article-title":"Solving neurodegeneration: common mechanisms and strategies for new treatments","author":"Wareham","year":"2022","journal-title":"Mol Neurodegener BioMed Central Ltd"},{"key":"10.1016\/j.diabres.2026.113345_b0020","first-page":"693","article-title":"Hallmarks of neurodegenerative diseases","author":"Wilson","year":"2023","journal-title":"Cell Elsevier BV"},{"key":"10.1016\/j.diabres.2026.113345_b0025","series-title":"Expert Opin Investig Drugs","first-page":"333","article-title":"Brain insulin resistance: role in neurodegenerative disease and potential for targeting","author":"H\u00f6lscher","year":"2020"},{"key":"10.1016\/j.diabres.2026.113345_b0030","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1212\/01.WNL.0000140292.04932.87","article-title":"Hyperinsulinemia and risk of Alzheimer disease","volume":"63","author":"Luchsinger","year":"2004","journal-title":"Neurology Wolters Kluwer"},{"issue":"2","key":"10.1016\/j.diabres.2026.113345_b0035","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/obr.12629","article-title":"Obesity as a risk factor for Alzheimer's disease: weighing the evidence","volume":"19","author":"Alford","year":"2018","journal-title":"Obes Rev"},{"key":"10.1016\/j.diabres.2026.113345_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2026.156494","article-title":"Emerging incretin- and multi-agonist-based treatments - the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond","volume":"177","author":"Muzurovi\u0107","year":"2026","journal-title":"Metabolism"},{"key":"10.1016\/j.diabres.2026.113345_b0045","series-title":"Pharmacological Approaches Using Diabetic Drugs Repurposed for Alzheimer\u2019s Disease","author":"Adem","year":"2024"},{"key":"10.1016\/j.diabres.2026.113345_b0050","series-title":"GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer\u2019s Disease Therapy","author":"Z\u0142otek","year":"2023"},{"key":"10.1016\/j.diabres.2026.113345_b0055","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s11011-025-01555-4","article-title":"Unveiling the mTOR pathway modulation by SGLT2 inhibitors: a novel approach to Alzheimer\u2019s disease in type 2 diabetes","volume":"40","author":"Ramakrishan","year":"2025","journal-title":"Metab Brain Dis"},{"key":"10.1016\/j.diabres.2026.113345_b0060","article-title":"Glucose metabolic dysfunction in neurodegenerative diseases\u2014new mechanistic insights and the potential of hypoxia as a prospective therapy targeting metabolic reprogramming","author":"Han","year":"2021","journal-title":"Int J Mol Sci MDPI"},{"key":"10.1016\/j.diabres.2026.113345_b0065","series-title":"Ann N Y Acad Sci","first-page":"180","article-title":"Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer\u2019s disease","author":"Mosconi","year":"2008"},{"key":"10.1016\/j.diabres.2026.113345_b0070","doi-asserted-by":"crossref","DOI":"10.1097\/RLU.0000000000002948","article-title":"Longitudinal 18F-FDG images in patients with Alzheimer disease over more than 9 years from a preclinical stage","volume":"45","author":"Ishibashi","year":"2020","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.diabres.2026.113345_b0075","unstructured":"Pietrini P, Furey ML, Guarzelli M, Alexander GE. 8 Functional Brain Studies of the Neurometabolic Bases of Cognitive and Behavioral Changes in Alzheimer\u2019s Disease."},{"key":"10.1016\/j.diabres.2026.113345_b0080","series-title":"Alzheimer\u2019s and Dementia","first-page":"478","article-title":"Brain energy failure in dementia syndromes: Opportunities and challenges for glucagon-like peptide-1 receptor agonists","author":"Yassine","year":"2022"},{"key":"10.1016\/j.diabres.2026.113345_b0085","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.neurobiolaging.2013.09.033","article-title":"Impaired glycemia increases disease progression in mild cognitive impairment","volume":"35","author":"Morris","year":"2014","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.diabres.2026.113345_b0090","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1172\/JCI64595","article-title":"Alzheimer\u2019s disease and insulin resistance: Translating basic science into clinical applications","volume":"123","author":"De Felice","year":"2013","journal-title":"J Clin Investig"},{"key":"10.1016\/j.diabres.2026.113345_b0095","doi-asserted-by":"crossref","unstructured":"Antal B, Mcmahon LP, Fahad Sultan S, Lithen A, Wexler DJ, Dickerson B, et al. Type 2 diabetes mellitus accelerates brain aging and cognitive decline: Complementary findings from UK Biobank and meta-analyses. DOI: 10.7554\/eLife.","DOI":"10.7554\/elife"},{"key":"10.1016\/j.diabres.2026.113345_b0100","series-title":"J Neuroinflammation","article-title":"Effects of diabetes on microglial physiology: a systematic review of in vitro, preclinical and clinical studies","author":"Vargas-Soria","year":"2023"},{"key":"10.1016\/j.diabres.2026.113345_b0105","series-title":"Neurochem Int","article-title":"Insulin signaling pathway and related molecules: Role in neurodegeneration and Alzheimer\u2019s disease","author":"Akhtar","year":"2020"},{"key":"10.1016\/j.diabres.2026.113345_b0110","series-title":"Neural Regen. Res","first-page":"1652","article-title":"Parkinson\u2019s disease and diabetes mellitus: common mechanisms and treatment repurposing","author":"Labandeira","year":"2022"},{"key":"10.1016\/j.diabres.2026.113345_b0115","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1172\/JCI59903","article-title":"Demonstrated brain insulin resistance in Alzheimer\u2019s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline","volume":"122","author":"Talbot","year":"2012","journal-title":"J Clin Investig"},{"key":"10.1016\/j.diabres.2026.113345_b0120","series-title":"Alzheimer\u2019s and Dementia","article-title":"The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer\u2019s disease","author":"Talbot","year":"2014"},{"key":"10.1016\/j.diabres.2026.113345_b0125","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1001\/jamaneurol.2015.0613","article-title":"Association of insulin resistance with cerebral glucose uptake in late middle\u2013aged adults at risk for Alzheimer Disease","volume":"72","author":"Willette","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.diabres.2026.113345_b0130","series-title":"Neuropharmacology","article-title":"Peripheral versus central insulin and leptin resistance: role in metabolic disorders, cognition, and neuropsychiatric diseases","author":"Erichsen","year":"2022"},{"issue":"1","key":"10.1016\/j.diabres.2026.113345_b0135","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.metabol.2014.07.004","article-title":"Leptin and the brain: influences on brain development, cognitive functioning and psychiatric disorders","volume":"64","author":"Farr","year":"2015","journal-title":"Metabolism"},{"key":"10.1016\/j.diabres.2026.113345_b0140","series-title":"Signal Transduct. Target. Ther.","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","author":"Zheng","year":"2024"},{"key":"10.1016\/j.diabres.2026.113345_b0145","series-title":"Pharmacol Ther","article-title":"GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?","author":"Arredouani","year":"2025"},{"issue":"5","key":"10.1016\/j.diabres.2026.113345_b0150","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s00125-016-3874-y","volume":"59","author":"Farr","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2026.113345_b0155","series-title":"Front. Endocrinol (Lausanne)","article-title":"Mechanisms underlying cognitive impairment and management strategies in type 2 diabetes","author":"Chen","year":"2025"},{"key":"10.1016\/j.diabres.2026.113345_b0160","series-title":"J. Neurol. Neurosurg. Psychiatry.","first-page":"870","article-title":"Glucagon-like peptide-1 receptor agonists for major neurocognitive disorders","author":"De Giorgi","year":"2025"},{"key":"10.1016\/j.diabres.2026.113345_b0165","article-title":"Neurodegeneration and stroke after semaglutide and tirzepatide in patients with diabetes and obesity","volume":"8","author":"Lin","year":"2025","journal-title":"JAMA Netw Open American Medical Association"},{"key":"10.1016\/j.diabres.2026.113345_b0170","series-title":"J Neurol. Springer Science and Business Media Deutschland GmbH","first-page":"3417","article-title":"Comparing major and mild cognitive impairment risks in older type-2 diabetic patients: a Danish register-based study on dipeptidyl peptidase-4 inhibitors vs. glucagon-like peptide-1 analogues","author":"Battini","year":"2024"},{"key":"10.1016\/j.diabres.2026.113345_b0175","series-title":"Alzheimer\u2019s and Dementia: Translational Research and Clinical Interventions","article-title":"Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers","author":"N\u00f8rgaard","year":"2022"},{"key":"10.1016\/j.diabres.2026.113345_b0180","series-title":"EClinicalMedicine","article-title":"Comparative effectiveness of glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitors, and sulfonylureas on the risk of dementia in older individuals with type 2 diabetes in Sweden: an emulated trial study","author":"Tang","year":"2024"},{"key":"10.1016\/j.diabres.2026.113345_b0185","series-title":"Diabetes Obes Metab","article-title":"Comparative effectiveness of SGLT2 sodium-glucose cotransporter-2 inhibitors and GLP-1 glucagon-like peptide-1 receptor agonists for incident dementia: A retrospective multicohort study","author":"Anagnostakis","year":"2025"},{"key":"10.1016\/j.diabres.2026.113345_b0190","series-title":"SGLT2 Inhibitors: From Molecular Mechanisms to Clinical Outcomes in Cardiology and Diabetology","author":"Stielow","year":"2025"},{"key":"10.1016\/j.diabres.2026.113345_b0195","series-title":"Therapy on Dementia and Cognitive Decline. Biomedicines","article-title":"Impact of Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)","author":"Lardaro","year":"2024"},{"key":"10.1016\/j.diabres.2026.113345_b0200","series-title":"Int J Mol Sci","article-title":"The role of sodium-glucose Co-transporter-2 inhibitors on diuretic resistance in heart failure","author":"Stachteas","year":"2024"},{"key":"10.1016\/j.diabres.2026.113345_b0205","series-title":"Diab Vasc Dis Res","article-title":"The association between sodium-glucose cotransporter 2 inhibitors and incident dementia: a nationwide population-based longitudinal cohort study","author":"Siao","year":"2022"},{"key":"10.1016\/j.diabres.2026.113345_b0210","series-title":"Alzheimer\u2019s and Dementia","first-page":"5528","article-title":"Heterogeneous treatment effects of sodium-glucose cotransporter 2 inhibitors on risk of dementia in people with type 2 diabetes: A population-based cohort study","author":"Tang","year":"2024"},{"key":"10.1016\/j.diabres.2026.113345_b0215","series-title":"Diabetes Obes Metab","first-page":"3766","article-title":"Sodium-glucose cotransporter-2 inhibitors and subtype-specific dementia risk: A multinational and multiethnic cohort study","author":"Sun","year":"2025"},{"key":"10.1016\/j.diabres.2026.113345_b0220","series-title":"Diabetes Obes Metab","article-title":"Baseline HbA1c and dementia risk at SGLT2i initiation in type 2 diabetes","author":"Zhang","year":"2025"},{"key":"10.1016\/j.diabres.2026.113345_b0225","series-title":"J Am Heart Assoc","article-title":"Activation of glucagon-like peptide-1 receptor ameliorates cognitive decline in type 2 diabetes mellitus through a metabolism-independent pathway","author":"Li","year":"2021"},{"key":"10.1016\/j.diabres.2026.113345_b0230","article-title":"Comparison between the effects of sitagliptin and liraglutide on blood glucose and cognitive function of patients with both type 2 diabetes mellitus and post-stroke mild cognitive impairment","author":"Wang","year":"2020","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.diabres.2026.113345_b0235","series-title":"Int J Obes","first-page":"1254","article-title":"Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study","author":"Vadini","year":"2020"},{"key":"10.1016\/j.diabres.2026.113345_b0240","article-title":"In Alzheimer\u2019s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: Randomized, placebo-controlled, double-blind clinical trial","volume":"8","author":"Gejl","year":"2016","journal-title":"Front Aging Neurosci Frontiers Media SA"},{"key":"10.1016\/j.diabres.2026.113345_b0245","article-title":"Blood-brain glucose transfer in Alzheimer\u2019s disease: effect of GLP-1 analog treatment","volume":"7","author":"Gejl","year":"2017","journal-title":"Sci Rep Nat Publ Group"},{"key":"10.1016\/j.diabres.2026.113345_b0250","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41591-025-04106-7","article-title":"Liraglutide in mild to moderate Alzheimer\u2019s disease: a phase 2b clinical trial","volume":"32","author":"Edison","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.diabres.2026.113345_b0255","series-title":"The Lancet","article-title":"Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson\u2019s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial","author":"Vijiaratnam","year":"2025"},{"key":"10.1016\/j.diabres.2026.113345_b0260","series-title":"J Endocrinol Invest","first-page":"2339","article-title":"Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: a proof-of-concept clinical trial","author":"Dei Cas","year":"2024"},{"key":"10.1016\/j.diabres.2026.113345_b0265","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2174\/1567205016666190913155950","article-title":"A pilot study of exenatide actions in Alzheimer\u2019s disease","volume":"16","author":"Mullins","year":"2019","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.diabres.2026.113345_b0270","series-title":"The Lancet","first-page":"1664","article-title":"Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial","author":"Athauda","year":"2017"},{"key":"10.1016\/j.diabres.2026.113345_b0275","series-title":"J Parkinsons Dis","first-page":"247","article-title":"What effects might exenatide have on non-motor symptoms in Parkinson\u2019s disease: a post Hoc analysis","author":"Athauda","year":"2018"},{"key":"10.1016\/j.diabres.2026.113345_b0280","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson\u2019s disease","volume":"123","author":"Aviles-Olmos","year":"2013","journal-title":"J Clin Investig"},{"key":"10.1016\/j.diabres.2026.113345_b0285","first-page":"337","article-title":"Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson\u2019s disease","volume":"4","author":"Aviles-Olmos","year":"2015","journal-title":"J Parkinsons Dis IOS Press BV"},{"key":"10.1016\/j.diabres.2026.113345_b0290","first-page":"1176","article-title":"Trial of Lixisenatide in Early Parkinson\u2019s Disease","volume":"390","author":"Meissner","year":"2024","journal-title":"New England J Med Massachusetts Med Soc"},{"key":"10.1016\/j.diabres.2026.113345_b0295","series-title":"Lancet Neurol","first-page":"37","article-title":"Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial","author":"McGarry","year":"2024"},{"key":"10.1016\/j.diabres.2026.113345_b0300","article-title":"The research of dapagliflozin on cognitive function in middle-aged and older patients with type 2 diabetes mellitus and mild cognitive impairment: a 36-week prospective parallel control study","volume":"1002","author":"Ding","year":"2025","journal-title":"Eur J Pharmacol Elsevier BV"},{"key":"10.1016\/j.diabres.2026.113345_b0305","series-title":"Alzheimer\u2019s and Dementia.","article-title":"Effects of the SGLT2 inhibitor dapagliflozin in early Alzheimer\u2019s disease: A randomized controlled trial","author":"Burns","year":"2025"},{"key":"10.1016\/j.diabres.2026.113345_b0310","doi-asserted-by":"crossref","DOI":"10.18502\/ijph.v51i6.9668","article-title":"Effect of dapagliflozin combined with cognitive behavior training on quality of life and cognitive function in elderly patients with type 2 diabetes mellitus complicated with mild cognitive impairment","author":"Zhao","year":"2022","journal-title":"Iran J Public Health"},{"key":"10.1016\/j.diabres.2026.113345_b0315","series-title":"Alzheimer\u2019s and Dementia","article-title":"A phase 2A\/B randomized trial of metabolic modulators intranasal insulin and empagliflozin for MCI and early AD","author":"Erichsen","year":"2025"},{"key":"10.1016\/j.diabres.2026.113345_b0320","series-title":"Diabetes Care","first-page":"1201","article-title":"Enhancement of impaired olfactory neural activation and cognitive capacity by liraglutide, but not dapagliflozin or acarbose, in patients with type 2 diabetes: a 16-week randomized parallel comparative study","author":"Cheng","year":"2022"},{"key":"10.1016\/j.diabres.2026.113345_b0325","series-title":"Clin Pharmacol.","first-page":"141","article-title":"12-month effects of incretins versus SGLT2-inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with type-2 diabetes mellitus","author":"Perna","year":"2018"},{"issue":"3","key":"10.1016\/j.diabres.2026.113345_b0330","doi-asserted-by":"crossref","first-page":"494","DOI":"10.11124\/JBIES-22-00430","article-title":"The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials","volume":"21","author":"Barker","year":"2023","journal-title":"JBI Evidence Synth"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726002652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726002652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:35:56Z","timestamp":1780634156000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726002652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":66,"alternative-id":["S0168822726002652"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113345","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing GLP-1 receptor agonists and SGLT-2 inhibitors in neurodegeneration and metabolically at-risk populations: Myth or reality? An overview of randomized clinical trials","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113345","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113345"}}